SCHEDULE: FMR LLC Boosts Xenon Pharma Stake to 11.5%
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have reported an 11.5% beneficial ownership stake in XENON PHARMACEUTICALS INC common stock as of June 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively hold 8,824,363 shares of XENON PHARMACEUTICALS INC common stock.
- This represents an 11.5% beneficial ownership stake in the company.
- The filing is an Amendment No. 6 to Schedule 13G, indicating a passive investment position.
- FMR LLC holds sole voting power over 8,824,348 shares and sole dispositive power over 8,824,363 shares.
- Abigail P. Johnson holds sole dispositive power over 8,824,363 shares.
- The ownership is held on behalf of various clients, with no single client holding more than 5% of the total outstanding common stock.
- Key entities under FMR LLC include FIAM LLC, Fidelity Institutional Asset Management Trust Company, and Fidelity Management & Research Company LLC, with Fidelity Management & Research Company LLC beneficially owning 5% or more of the outstanding shares.
Sentiment
Score: 7
Explanation: The filing indicates a substantial 11.5% beneficial ownership by FMR LLC, a prominent institutional investor, which generally signals confidence in the company's long-term prospects. The passive nature of the investment (13G filing) suggests it is for investment purposes rather than control.
Positives
- Significant institutional investment from FMR LLC, a major asset manager, signals confidence in XENON PHARMACEUTICALS INC.
- The 11.5% stake indicates a substantial, long-term passive investment, which can provide stability to the shareholder base.
Risks
- No specific risks related to XENON PHARMACEUTICALS INC's operations or financial health are disclosed in this ownership filing, as it primarily reports beneficial ownership.
Future Outlook
NA
Industry Context
This filing indicates continued or increased institutional interest in the pharmaceutical/biotechnology sector, specifically in XENON PHARMACEUTICALS INC, from a major asset management firm like FMR LLC.
Stakeholder Impact
- Shareholders: Increased institutional ownership by a reputable firm like FMR LLC can be viewed positively, potentially enhancing investor confidence and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2023-05-23 | Effective date of Power of Attorney for Richard Bourgelas. |
| 2023-08-08 | Date of previous Schedule 13G filing by FMR LLC (accession number -23-002397) where the Power of Attorney was incorporated by reference. |
| 2025-06-30 | Date of event which requires filing of this statement, representing the reporting period end date for beneficial ownership. |
| 2025-08-05 | Date of signing and joint filing agreement for this Schedule 13G Amendment No. 6. |
Recommendation
holdThe filing indicates a significant, passive institutional stake by FMR LLC, which is a positive signal of confidence. However, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data that would warrant a change in investment recommendation. Without additional fundamental analysis of XENON PHARMACEUTICALS INC's business, the current information supports holding the stock based on this ownership disclosure.
Keywords
Xenon Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.